MindWalk Revenue Jumps 46% as Bio-Native AI Pivot Drives First Recurring Platform Deals
HYFT sits 44% above its 52-week low of $0.99.
Summary
MindWalk delivered a breakout fiscal 2026: revenue surged 46% to $15.6M, with Q4 revenue accelerating to 50% growth and reaching C$4.12M. Gross margin expanded to 59%, and net loss halved. The company completed its pivot to Bio-Native AI infrastructure, divested a non-core subsidiary for ~$14.3M, and signed its first two recurring enterprise LensAI deals—the first recurring platform revenue in its history. The balance sheet remains modest with $11.5M cash, but the $250M shelf and $50M ATM filed July 13 provide capital flexibility. Nasdaq compliance was regained organically, and a 2.3M-share buyback was authorized. The stock is a micro-cap at $1.42; the revenue trajectory and recurring deals could shift the narrative from concept to commercial execution.
At the time of this announcement, HYFT was trading at $1.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.3M. The 52-week trading range was $0.99 to $3.25. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.